Rabeprazole Levels and Effects while Breastfeeding
Summary of Use during Lactation
Because no information is available on the use of rabeprazole during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
A retrospective claims database study in the United States found that users of proton pump inhibitors had an increased risk of gynecomastia.[1]
The Spanish pharmacovigilance system found one case of a 90-year-old man who developed gynecomastia associated with rabeprazole reported during the time period of 1982 to 2006. The reaction occurred after 32 days of therapy and resolved after discontinuation of the drug.[2]
He B, Carleton B, Etminan M. Risk of gynecomastia with users of proton pump inhibitors. Pharmacotherapy. 2019;39:614–8. [PubMed: 30865318]
2.
Carvajal A, Macias D, Gutierrez A, et al. Gynaecomastia associated with proton pump inhibitors: A case series from the Spanish Pharmacovigilance System. Drug Saf. 2007;30:527–31. [PubMed: 17536878]
Substance Identification
Substance Name
Rabeprazole
CAS Registry Number
117976-89-3
Drug Class
Breast Feeding
Lactation
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.